Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

One of 51 (2.0%) patients in the ultra-early salvage ADT group developed biochemical recurrence, compared with 12 of 70 (17.1%) patients in the early salvage ADT group (Figure 1). Univariate analysis ...

- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in ...

Please provide your email address to receive an email when new articles are posted on . Staging from prostate-specific membrane androgen PET/CT had a significant association with PFS. Whole pelvis ...